UBS ties PolyPeptide returns to Samsung deal after strong half
The broker frames the contract manufacturer's upside around the Samsung agreement rather than its first-half performance.
TR
By Tom Reyes · Markets Editor
Oct 7 09:00 ETSource: Yahoo Finance Australia
The wire
- 01UBS said PolyPeptide's investment case now rests on its Samsung deal, despite the peptide contract manufacturer reporting a strong first half.
- 02PolyPeptide is a supplier of peptide active ingredients, so its capacity commitments matter to anyone tracking peptide drug supply.
- 03This is broker commentary rather than a company disclosure, and terms and volumes behind the Samsung arrangement are not detailed here.
From the source
Read at au.finance.yahoo.comUBS says PolyPeptide returns now hinge on Samsung deal despite strong half
